Related Experiment Video

Updated: May 12, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Challenges in the clinical development of PI3K inhibitors

Cristian Massacesi1, Emmanuelle di Tomaso, Nathalie Fretault

  • 1Novartis Oncology, Paris, France. cristian.massacesi@novartis.com

Annals of the New York Academy of Sciences
|April 5, 2013
PubMed

Insights

The PI3K/Akt/mTOR pathway is crucial in cancer, driving tumor growth and survival. Targeting this pathway with PI3K inhibitors offers a promising strategy for developing new anticancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The Phosphatidylinositol 3-kinase (PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) pathway is frequently dysregulated in various cancers.
  • This pathway is critical for fundamental cellular processes including proliferation, survival, motility, and angiogenesis, making it a key driver of tumorigenesis.

Purpose of the Study:

  • To highlight the significance of the PI3K/Akt/mTOR pathway as a target for cancer drug development.
  • To discuss the mechanisms of PI3K pathway activation in cancer.
  • To emphasize the need for structured clinical trial designs for PI3K inhibitors.

Main Methods:

  • Review of mechanisms leading to PI3K pathway activation.
  • Discussion of PI3K pathway's role in primary tumorigenesis and therapeutic resistance.
  • Overview of PI3K inhibitors in clinical development.

Main Results:

  • PI3K pathway activation in cancer can occur through receptor upregulation, PIK3CA mutations, or PTEN inactivation.
  • Pathway activation contributes to both initial tumor formation and the development of resistance to cancer treatments.
  • Numerous PI3K inhibitors are under investigation across various cancer types.

Conclusions:

  • The PI3K/Akt/mTOR pathway is a central signaling network in cancer, implicated in tumor development and treatment resistance.
  • Targeting this pathway with inhibitors represents a significant area of focus for novel anticancer drug development.
  • Effective clinical development of PI3K inhibitors necessitates adaptable and robust trial designs.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...